media – Page 4 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Nobel Prize-winning company lays off 90% of its staff

Recently, Caribou Biosciences announced the termination of development of all its clinical pipelines, large-scale layoffs, and the initiation of a strategic review that includes mergers, acquisitions, and asset sales. Under California’s WARN Act, Caribou will lay off 87 employees, effective December 7. The company had 97 full-time employees as of February 27, 2026, meaning the layoffs will affect approximately 90% of its workforce . Caribou’s co-founders include Jennifer Doudna, a pioneer of CRISPR gene editing technology and the 2020 Nobel Prize laureate in Chemistry; the company was also one of the first to bring CRISPR to clinical application. From Nobel Prize Labs to Nasdaq In 2011 , Jennifer Doudna’s Berkeley lab had just unveiled the CRISPR-Cas9 gene-editing tool when she and her PhD student, Rachel Haurwitz, co-founded Caribou Biosciences, with venture capital firm Atlas Venture providing $11 million in seed funding. In 2014, Caribou, along with Atlas Venture, spun off ...
- Source: drugdu
- 102
- October 26, 2026
Methionine raw material passes South Korea’s MFDS inspection

Tianjin Pharmaceutical Co., Ltd.On the evening of October 23, the company issued a statement saying that it had recently received the results of a GMP on-site inspection from the Korean Ministry of Food and Drug Safety (MFDS). From September 8th to 10th, Tianjin Pharmaceutical Group’s production base located at No. 19, Xinyejiu Street, West Zone, Tianjin Economic-Technological Development Area, received methionine raw material.The site underwent GMP inspection and passed the Korean MFDS requirements with “zero defects”. Methionine, an essential amino acid for the human body, is a core raw material for various amino acid infusions and compound amino acid preparations. Clinically, it is used as an adjunct treatment for chronic hepatitis and cirrhosis, as well as a supportive treatment for toxic liver disease. Industry insiders believe that the scope of this inspection focused on methionine raw materials , and passing with “zero defects” means that the company’s quality system, production ...
- Source: drugdu
- 93
- October 26, 2026
Clinical trial application submitted to the US FDA for ASC39 oral tablets for the treatment of obesity.

People’s Finance News, October 26th – Ascletis Pharma announced on the Hong Kong Stock Exchange that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its ASC39 oral tablets. ASC39 is an oral, small-molecule selective amylin receptor agonist used to treat obesity. The company expects to initiate a Phase I trial in the fourth quarter of 2026. Source: https://finance.eastmoney.com/a/202610263907436177.html
- Source: drugdu
- 84
- October 26, 2026
【EXPERT Q&A】‌‌With a large number of main products, which items should an enterprise prioritize for overseas promotion?‌

Drugdu.com expert’s response: When many pharmaceutical and medical device enterprises start overseas promotion, they will encounter a common problem: there are dozens or even hundreds of products in the company’s product catalog, but which ones should be prioritized for key promotion on B2B platforms? Some enterprises are used to uploading all their existing products, believing that the more products they list, the higher the chance of being searched by overseas buyers. Others directly select several best-selling products in the domestic market, assuming that items performing well at home will surely meet demands in overseas markets. Both ideas are reasonable to a certain extent, but more factors need to be taken into account in actual overseas procurement scenarios. Whether a product can attract buyers’ attention is related not only to market demand, but also to the enterprise’s supply capacity, product documentation, target market access status and peer competition. A Large Product ...
- Source: drugdu
- 129
- October 23, 2026
【EXPERT Q&A】‌To what extent should an enterprise prepare when overseas buyers inquire whether products can support local registration?‌

Drugdu.com expert’s response: When conducting foreign trade in pharmaceuticals and medical devices, some overseas buyers, after confirming product specifications and prices, will further ask: “Can you support product registration in our country?” This question may seem straightforward to suppliers. If an enterprise holds relevant certificates such as GMP, CE, or ISO 13485, or has past export experience, it can easily reply directly that it can support registration. However, the “registration support” mentioned by buyers may involve far more work than just providing a few certificates. Especially for pharmaceuticals, APIs and medical devices, there are significant differences in registration pathways, application entities, technical documents and approval requirements across different countries. The fact that a supplier can provide product materials does not mean these materials already meet local registration requirements; nor does the fact that a product has been approved for marketing in one market mean it can directly enter another. What Are ...
- Source: drugdu
- 134
- October 23, 2026
Pharma Asia Pakistan

Organiser：ECG (Pvt.) Ltd., Pakistan Time：October 20-22, 2026 Address：University Rd, Gulshan-e-Iqbal, Karachi, Pakistan Exhibition hall：Karachi Expo Center Product range: Medical Products Zone‌: Medical diagnostic equipment, electronic medical devices, ambulance equipment, medical reagents, medical apparatus ‌Hospital Supplies Zone‌: Catheters, interventional materials, surgical hygiene products, disposable medical consumables, surgical tools, medical uniforms, bedding supplies, first-aid equipment, maternal and infant care devices, disinfection equipment ‌Laboratory Equipment Zone‌: Laboratory instruments, optical instruments, image analysis and processing systems, testing instruments and devices, laboratory upgrading and transformation technologies, consumables, related software ‌Pharmaceuticals Zone‌: New special drugs, Chinese patent medicines, Western medicines, traditional Chinese medicine, health supplements, nutritional foods, traditional herbal medicines ‌Pharmaceutical Equipment Zone‌: Pharmaceutical production equipment, pharmaceutical packaging equipment, pharmaceutical packaging materials, pharmaceutical production cleaning and preparation systems, disinfection preparation systems About Pharma Asia Pakistan： Pharma Asia Pakistan showcases the latest medical and diagnostic devices as well as medical service facilities, offering exhibitors, buyers ...
- Source: drugdu
- 98
- October 22, 2026
InterPharma Jakarta

Organiser：Jakarta International Expo (JI EXPO), Indonesia Time：October 20-23, 2026 Address：Gedung Pusat Niaga, Arena JIExpo, Jl. Benyamin Suaeb, Kec. Kemayoran, Kota Jakarta Pusat, Daerah Khusus Ibukota Jakarta 10720, Indonesia Exhibition hall：Jakarta International Expo Product range: Raw Materials & Auxiliaries: APIs, Intermediates, Natural Extracts, Excipients, R&D and Production Services Custom Formulation Manufacturing Biological & Chemical Products: Biopharmaceuticals, Fine Chemicals Laboratory Equipment: Laboratory Instruments, Laboratory Apparatus, Water Treatment Quality & Environmental Control: Environmental and Quality Control Technologies, Publications Pharmaceutical Products: Medicines, Pharmaceutical Goods Packaging & Engineering: Pharmaceutical Engineering, Materials & Packaging, Pharmaceutical Machinery and Equipment About InterPharma Jakarta： InterPharma Jakarta, Indonesia is the largest and most influential pharmaceutical exhibition in Indonesia, and one of the key professional exhibitions for pharmaceuticals, medicines and packaging in Southeast Asia. Its display scope covers APIs, intermediates, biopharmaceuticals, medical supplies, material packaging, pharmaceutical machinery and more. The previous edition of InterPharma Jakarta covered a total area ...
- Source: drugdu
- 89
- October 20, 2026
FDA Approves Revolution Medicines’ Oral RAS Inhibitor Rasonque (daraxonrasib) for Metastatic Pancreatic Cancer

On October 19, 2026, the U.S. Food and Drug Administration (FDA) approved Rasonque (daraxonrasib), an oral RAS inhibitor from Revolution Medicines, Inc., for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy. The approval is based on a randomized, open-label, multicenter trial involving 500 adults with previously treated metastatic pancreatic adenocarcinoma. Participants received once-daily oral daraxonrasib or standard chemotherapy. The trial showed a median overall survival of 13.2 months with daraxonrasib versus 6.7 months with standard chemotherapy. Daraxonrasib targets multiple forms of the RAS protein, a key driver of tumor growth in most pancreatic adenocarcinomas, and the approved indication does not impose a biomarker-based eligibility criterion. The approval offers a new treatment option for pancreatic cancer patients, who have historically faced limited treatment choices and poor outcomes. The most common side effects reported with daraxonrasib included ...
- Source: drugdu
- 219
- October 20, 2026
Hansoh Pharma Enters Strategic ADC Collaboration with Roche Worth Over US$15.5 Billion

On the evening of October 19, 2026, Hansoh Pharmaceutical Group (03692.HK) announced that its wholly-owned subsidiaries Shanghai Hansoh Biomedical Co., Ltd., Changzhou Hansoh Pharmaceutical Co., Ltd. and Hansoh Bio, LLC (collectively, Hansoh) entered into a strategic collaboration and license agreement on October 17 with F. Hoffmann-La Roche Ltd. This marks the two companies’ second partnership in the antibody-drug conjugate (ADC) field. The collaboration spans a broad portfolio of ADC programs, comprising two preclinical Hansoh ADC programs and multiple ADC programs based on Roche-proposed targets and powered by Hansoh’s proprietary ADC technology platform. Under the agreement, Hansoh will lead the early development of the programs up to completion of global Phase Ia clinical trials, while Roche will be responsible for further worldwide development excluding the Chinese Mainland, Hong Kong, Macau and Taiwan. Hansoh retains all rights to develop, register and commercialize the programs within Greater China. Under the agreement, Hansoh will ...
- Source: drugdu
- 132
- October 20, 2026
New cough medicine launched

Recently, the National Medical Products Administration approved the marketing of Zihua Wenfei Zhike Granules , a Class 1.1 innovative traditional Chinese medicine submitted by Guangzhou Yuekang Biopharmaceutical Co., Ltd., a subsidiary of Yuekang Pharmaceutical , for the treatment of cough due to wind-cold lingering in the lungs . Cough is a common symptom of respiratory diseases, and post-infectious cough is particularly troublesome due to its prolonged course. Zihua Wenfei Zhike Granules are specifically indicated for cough due to wind-cold lingering in the lungs, providing a new medication option for patients with this syndrome whose illness lasts 3 to 6 weeks. From the perspective of the formulation, the product prescription is derived from an empirical formula that has been clinically verified over a long period of time . It is composed of six medicinal materials: Aster tataricus, Tussilago farfara, Belamcanda chinensis, dried ginger, mango kernel, and Schizonepeta tenuifolia. These herbs complement ...
- Source: drugdu
- 128
- October 20, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.